All In Biotech

Drug Trial Radar · NCT05989048

A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Zavegepant Intranasal (IN) for the Acute Treatment of Migraine in Asian Adults

Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,414 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,414

Actual

Start

Nov 29, 2023

Primary completion

May 30, 2025

Study completion May 30, 2025

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn how safe and effective zavegepant is compared to placebo in the acute treatment of migraine in Asian adults. Migraine is a very painful headache with other associated symptoms such as nausea, photophobia and phonophobia. A placebo is a harmless treatment that has no medical effect. This study is seeking for participants who: * have at least 1 year of migraine history before entering the study. * have 2 to 8 migraine headache attacks of moderate or severe intensity in each of the 3 months before entering the study. * have less than 15 days with headaches in each of the 3 months before entering the study. The headaches could be either due to migraine or not. The participants in this study will receive zavegepant or placebo through intranasal route. Intranasal means medicine which is given through nose. Zavegepant or placebo will be taken if the participants have a migraine headache of moderate or severe intensity. The study will compare the experiences of people receiving zavegepant to those of the people receiving placebo. This will help see if zavegepant is safe and effective in Asian adults. Participants will be in this study for up to about 16 weeks. Participants will have 3 study visits at the study clinic and 1 through telephone contact.

Conditions

  • Migraine

Interventions

  • ZavegepantDrug

    The participants will receive single active dose sufficient to treat 1 migraine headache of moderate or severe intensity within Treatment Phase.

  • PlaceboDrug

    Single dose of matching placebo taken within Treatment Phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Pain Freedom at 2 Hours Post-doseTime frame: At 2 hours post-dose
  2. Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-doseTime frame: At 2 hours post-dose

Locations

61 sites in 3 countries. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, China

  • Xuanwu Hospital Capital Medical University

    Beijing, China

  • Chongqing University Three Gorges Hospital

    Chongqing, China

  • The fourth people's hospital of chongqing

    Chongqing, China

  • Shanghai East Hospital

    Shanghai, China

  • Tianjin Union Medical Center

    Tianjin, China

  • The Second People's hospital of Hefei

    Hefei, Anhui, China

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • The First Medical Center of Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Hainan General Hospital

    Haikou, Hainan, China

  • Renmin Hospital Of Wuhan University

    Wuhan, Hebei, China

  • The First Affiliated Hospital of Henan University of Science &Technology

    Luoyang, Henan, China

  • The First Affiliated Hospital of Henan University of Science &Technology

    Luoyang, Henan, China

  • People's Hospital of Zhengzhou

    Zhengzhou, Henan, China

  • Wuhan Third Hospital

    Wuhan, Hubei, China

  • Changsha Central Hospital

    Changsha, Hunan, China

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The Second People's Hospital of Lianyungang

    Lianyungang, Jiangsu, China

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Wuxi People's Hospital

    Wuxi, Jiangsu, China

  • Affiliated Hospital of Jiangnan University

    Wuxi, Jiangsu, China

  • The Affiliated Hospital of Jiangsu University

    Zhenjiang, Jiangsu, China

  • Pingxiang People's Hospital

    Pingxiang, Jiangxi, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • The People's Hospital of Liaoning Province

    Shenyang, Liaoning, China

  • The First People's Hospital of Yinchuan

    Yinchuan, Ningxia, China

  • General Hospital of Ningxia Medical Hospital

    Yinchuan, Ningxia, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China

  • Shaanxi Provincial People' Hospital

    Xi'an, Shaanxi, China

  • Xian Gaoxin Hospital

    Xi'an, Shaanxi, China

  • Xianyang Hospital of Yan'an University

    Xianyang, Shaanxi, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Jinan Central Hospital

    Jinan, Shandong, China

  • Affiliated Hospital of Jining Medical University

    Jining, Shandong, China

  • Liaocheng people's Hospital

    Liaocheng, Shandong, China

  • Qingdao Central Hospital

    Qingdao, Shandong, China

  • People's Hospital of Rizhao

    Rizhao, Shandong, China

  • Huashan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.